modelR03BA09

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:FluticasoneFuroate
ATC code:R03BA09
route:inhalation
compartments:2
dosage:100mg
volume of distribution:608L
clearance:58.7L/h
other parameters in model implementation

Fluticasone furoate is a synthetic corticosteroid with potent anti-inflammatory activity. It is used primarily in the management of asthma and allergic rhinitis. The drug is approved and widely used today as an inhaled therapy for the control and prevention of respiratory tract inflammation.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after single inhaled administration, fasted, both sexes.

References

  1. Siederer, S, et al., & Yang, S (2016). Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. European journal of drug metabolism and pharmacokinetics 41(6) 743–758. DOI:10.1007/s13318-015-0303-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26474864

  2. Mehta, R, et al., & Lipson, DA (2018). Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. Journal of clinical pharmacology 58(11) 1461–1467. DOI:10.1002/jcph.1253 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29762864

  3. Allen, A, et al., & Yang, S (2016). Population pharmacokinetics of inhaled fluticasone furoate and vilanterol in adult and adolescent patients with asthma. International journal of clinical pharmacology and therapeutics 54(4) 269–281. DOI:10.5414/CP202438 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26902504

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)